Home/Filings/4/0000899243-22-031404

4//SEC Filing

AFEYAN NOUBAR 4

Accession 0000899243-22-031404

CIK 0001659352other

View on SEC.gov Company Profile

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 7:30 PM ET

Size

19.3 KB

Accession

0000899243-22-031404

Insider Transaction Report

Form 4

Period: 2022-09-15

Codiak BioSciences, Inc.CDAK

Flagship Ventures Fund V General Partner LLC

10% Owner

Transactions

Purchase
Common Stock
2022-09-15+722,590→ 1,865,767 total(indirect: By Flagship Ventures Fund V, L.P.)
Purchase
Common Stock
2022-09-15+210,743→ 1,188,920 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.)
Purchase
Warrants to purchase Common Stock
2022-09-15+722,590→ 722,590 total(indirect: By Flagship Ventures Fund V, L.P.)
Exercise: $1.88From: 2022-09-15Exp: 2027-09-15→ Common Stock (722,590 underlying)
Purchase
Warrants to purchase Common Stock
2022-09-15+210,743→ 210,743 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.)
Exercise: $1.88From: 2022-09-15Exp: 2027-09-15→ Common Stock (210,743 underlying)

Holdings

Common Stock
(indirect: By LLC)
485,949

Flagship Ventures Fund V, L.P.

10% Owner

Transactions

Purchase
Warrants to purchase Common Stock
2022-09-15+210,743→ 210,743 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.)
Exercise: $1.88From: 2022-09-15Exp: 2027-09-15→ Common Stock (210,743 underlying)
Purchase
Common Stock
2022-09-15+722,590→ 1,865,767 total(indirect: By Flagship Ventures Fund V, L.P.)
Purchase
Common Stock
2022-09-15+210,743→ 1,188,920 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.)
Purchase
Warrants to purchase Common Stock
2022-09-15+722,590→ 722,590 total(indirect: By Flagship Ventures Fund V, L.P.)
Exercise: $1.88From: 2022-09-15Exp: 2027-09-15→ Common Stock (722,590 underlying)

Holdings

Common Stock
(indirect: By LLC)
485,949

Flagship V VentureLabs Rx Fund, L.P.

10% Owner

Transactions

Purchase
Common Stock
2022-09-15+722,590→ 1,865,767 total(indirect: By Flagship Ventures Fund V, L.P.)
Purchase
Common Stock
2022-09-15+210,743→ 1,188,920 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.)
Purchase
Warrants to purchase Common Stock
2022-09-15+722,590→ 722,590 total(indirect: By Flagship Ventures Fund V, L.P.)
Exercise: $1.88From: 2022-09-15Exp: 2027-09-15→ Common Stock (722,590 underlying)
Purchase
Warrants to purchase Common Stock
2022-09-15+210,743→ 210,743 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.)
Exercise: $1.88From: 2022-09-15Exp: 2027-09-15→ Common Stock (210,743 underlying)

Holdings

Common Stock
(indirect: By LLC)
485,949

AFEYAN NOUBAR

10% Owner

Transactions

Purchase
Common Stock
2022-09-15+722,590→ 1,865,767 total(indirect: By Flagship Ventures Fund V, L.P.)
Purchase
Common Stock
2022-09-15+210,743→ 1,188,920 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.)
Purchase
Warrants to purchase Common Stock
2022-09-15+722,590→ 722,590 total(indirect: By Flagship Ventures Fund V, L.P.)
Exercise: $1.88From: 2022-09-15Exp: 2027-09-15→ Common Stock (722,590 underlying)
Purchase
Warrants to purchase Common Stock
2022-09-15+210,743→ 210,743 total(indirect: By Flagship V VentureLabs Rx Fund, L.P.)
Exercise: $1.88From: 2022-09-15Exp: 2027-09-15→ Common Stock (210,743 underlying)

Holdings

Common Stock
(indirect: By LLC)
485,949

Footnotes (4)

[F1]On September 15, 2022, pursuant to an underwritten public offering by the Issuer (the "Offering"), Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 722,590 shares of Common Stock and accompanying warrants to purchase 722,590 shares of Common Stock, and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") acquired 210,743 shares of Common Stock and accompanying warrants to purchase 210,743 shares of Common Stock. The combined purchase price in the Offering was $1.50 per share of Common Stock and accompanying warrant.
[F2]Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
[F3]Shares held by Flagship Fund V Rx. Flagship V GP is the general partner of Flagship Fund V Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
[F4]Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Codiak BioSciences, Inc.

CIK 0001659352

→

Entity typeother

Related Parties

filerCIK 0001222012

Filing Metadata

Form type: 4
Filed: Sep 15, 8:00 PM ET
Accepted: Sep 16, 7:30 PM ET
Size: 19.3 KB

View on SEC.gov